SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bristol-Myers Squibb Company: Orencia(R) (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years

June 12, 2009 | 
1 min read
COPENHAGEN--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of two ORENCIA® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held in Copenhagen, Denmark.
Clinical research Phase II Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Retro collage hand holding pie chart diagram. Business data and market share concept. Modern retro grunge. Vector illustration
Gene therapy
Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths
August 13, 2025
 · 
2 min read
 · 
Tristan Manalac
The female hand is showing a thumbs-up gesture on a pink background, in an art collage. Positive hand sign. Fashion collage in the style of thumbs up magazine. Contemporary art. Modern design.
Lung cancer
140-Year-Old Boehringer Ingelheim Dives Into Cancer With NSCLC Nod
August 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of application new technology in future medicine
IN PARTNERSHIP WITH TOZARO
The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges
August 11, 2025
 · 
8 min read
 · 
BioSpace Insights
Composite photo collage of human doctor hand wear glove hold corona pandemic biohazard illness diagnostics isolated on painted background.
Gene therapy
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light
August 11, 2025
 · 
7 min read
 · 
Dan Samorodnitsky